Kinnate Biopharma Inc. (KNTE)


-0.15 (-3.62%)
Symbol KNTE
Price $3.99
Beta 0.211
Volume Avg. 0.44M
Market Cap 185.825M
Shares () -
52 Week Range 2.32-15.86
1y Target Est -
DCF Unlevered KNTE DCF ->
DCF Levered KNTE LDCF ->
ROE -65.39% Strong Sell
ROA -61.06% Strong Sell
Operating Margin -
Debt / Equity 9.11% Neutral
P/E -1.38 Sell
P/B 0.79 Buy


Consensus EPS

Upgrades & Downgrades

Latest KNTE news

Mr. Nima Farzan M.B.A.
NASDAQ Global Select

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.